Synthesis of Carbon‐13 and Carbon‐14 Labeled BI 690517 (Vicadrostat) and Its O ‐Glucuronide Metabolite BI 689875
Journal of Labelled Compounds and Radiopharmaceuticals · 2026-04 · 69 (4-6)
DOI: 10.1002/jlcr.70026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, online erschienen am 07.04.2026. Verfasst von Bachir Latli und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA. Hauptthemen laut MEDLINE: Carbon Radioisotopes, Glucuronides. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Vicadrostat, also known as BI 690517 ( 1 ) is a novel, potent, and selective aldosterone synthase CYP11B2 inhibitor being developed in combination with empagliflozin to slow the progression of kidney damage and reduce cardiovascular events in people with chronic kidney diseases (CDK). The stable isotope labeled BI 690517 was obtained in a 12‐step synthesis starting from aniline‐ 13 C 6 . The product was isolated with high chemical purity and enantiomeric excess. Carbon‐14 labeled BI 690517 was prepared in one radioactive step from a chiral iodo‐analog BI 764437 and zinc cyanide‐ 14 C . [ 14 C]‐1 was obtained with a specific activity of 55.6 mCi/mmol (2.05 GBq/mmol), chemical and radiochemical purities higher than 98%, and with enantiomeric excess higher than 99%. Vicadrostat undergoes extensive hepatic glucuronidation to form the O ‐glucuronide BI 689875 ( 2 ). Both carbon‐13 and carbon‐14 labeled BI 689875 were also synthesized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.
ORCID-Profile: Bachir Latli, Nizar Haddad
Zitieren
APA
Latli, B., Hrapchak, M., Chevliakov, M., Samankumara, L., Khattabi, S., & Haddad, N. (2026). Synthesis of Carbon‐13 and Carbon‐14 Labeled BI 690517 (Vicadrostat) and Its O ‐Glucuronide Metabolite BI 689875. Journal of Labelled Compounds and Radiopharmaceuticals, 69(4-6). https://doi.org/10.1002/jlcr.70026
Vancouver
Latli B, Hrapchak M, Chevliakov M, Samankumara L, Khattabi S, Haddad N. Synthesis of Carbon‐13 and Carbon‐14 Labeled BI 690517 (Vicadrostat) and Its O ‐Glucuronide Metabolite BI 689875. Journal of Labelled Compounds and Radiopharmaceuticals. 2026;69(4-6). doi:10.1002/jlcr.70026
BibTeX
@article{Latli2026,
author = {Latli, Bachir and Hrapchak, Matt and Chevliakov, Maxim and Samankumara, Lalith and Khattabi, Saad and Haddad, Nizar},
title = {Synthesis of Carbon‐13 and Carbon‐14 Labeled BI 690517 (Vicadrostat) and Its O ‐Glucuronide Metabolite BI 689875},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2026},
volume = {69},
number = {4-6},
doi = {10.1002/jlcr.70026}
}
EUVIMED